Post by PCI Pharma Services

When every batch matters, rare disease drug development demands a different approach. For sponsors working with small patient populations, low-volume programs can bring significant technical and operational complexity. Highly potent molecules, microgram-level dosing, containment requirements, and global supply all need to be considered from the earliest stages of development. In his latest article for Pharmaceutical Technology, David O'Connell, Director, Scientific and Technical Affairs at PCI Pharma Services, explores how an integrated CDMO approach can support rare disease programs from formulation and clinical supply through packaging, multilingual labeling, and commercial distribution. When a single batch can represent a meaningful share of global supply, continuity across each stage becomes critical. Read the article to explore the infrastructure needed to develop, release, and deliver rare disease therapies with precision. https://lnkd.in/enE2NAka #RareDisease #DrugDevelopment #PharmaceuticalManufacturing #CDMO #LetsTalkFuture